Reflections from AHNTI 2026: Innovation, Customer-Centricity & The Evolving Landscape of Animal Health

Last week, Eirgen Pharma attended the Animal Health, Nutrition and Technology Innovation Europe Summit (AHNTI 2026) for the first time as exhibitors. While it was our debut in this community, we’ve spent over a decade supporting both human and animal health companies in developing and manufacturing complex therapeutics.

Being at AHNTI offered a unique chance to connect with innovators, partners, and companies shaping the future of animal health. Across panels, workshops, and showcases, one thing stood out - the sector is evolving rapidly, driven by technology, changing market dynamics, and an ever-stronger focus on customer value.

A Customer-Centric Industry at its Core

A recurring theme at AHNTI was the importance of understanding real-world needs. In animal health, this goes beyond commercial stakeholders—it reaches the animals themselves, veterinarians, and pet owners.

Meaningful innovation stems from addressing real challenges; supporting veterinarians in clinical decision-making, improving affordability for pet owners, and developing therapies that deliver measurable outcomes in practice. Customer-centricity isn’t just a strategy—it’s the purpose of the industry.

Four Trends Shaping the Future of Animal Health

Innovation Is Expanding Beyond Large Pharma

The sector is seeing more contributions from start-ups and emerging companies. In 2025, five new companion animal products were approved, reflecting agile innovation alongside established pharma. This diversity encourages collaboration across the sector and reshapes the development landscape. Current development focus areas breakdown includes;

Shifting Go-To-Market Dynamics

Commercial strategies within animal health are also evolving rapidly, particularly across the United States.

• Growth in alternative B2B distribution channels

• Increased direct-to-consumer purchasing by pet owners

• Ongoing consolidation of veterinary clinics, shifting purchasing decisions to larger corporate groups

Companies must now align development and commercial strategies with these evolving dynamics.

Artificial Intelligence Across the Value Chain

AI is emerging as a transformative force.

• R&D: Accelerating drug discovery and clinical development

• Manufacturing: Improving efficiency and supply chain visibility

• Commercial: Driving data-informed customer engagement

• Clinical care: Supporting diagnostics and veterinary decision-making

  
  

AI adoption is expected in three phases: immediate workflow optimization, mid-term predictive analytics, and long-term personalized treatments.

An Incredibly Competitive Generics Landscape

The generics market is also becoming more complex and competitive. Several trends appear to be contributing to this shift.

• Entry from global manufacturers

• Diverse generic offerings, from cost-focused to highly specialized

• Increasing online purchasing

• Shift toward corporate veterinary groups

Success requires differentiation, technical expertise, and strategic partnerships.

---

Key Conversations at AHNTI

Our discussions with partners and potential collaborators highlighted several industry priorities. Pipelines are becoming technically complex, creating demand for specialized development, formulation, and high-containment manufacturing capabilities. Companies are moving from transactional projects to co-development, early-stage technical collaboration, and integrated manufacturing partnerships. Manufacturers face pressure to deliver reliable global supply, efficient technology transfer, cost-effective production, and consistent quality—ensuring therapies reach veterinarians and pet owners efficiently.

---

Looking Ahead

AHNTI reinforced that animal health is at a transformative moment. Pipelines are expanding, therapeutics are becoming more specialized, and market dynamics are shifting - creating both complexity and opportunity.

For Eirgen Pharma, this underscores the value of deep collaboration, translating scientific innovation into scalable, reliable therapies that reach the market successfully.

If your organization is exploring development opportunities, our team is ready to continue the conversation.

Contact our team here.